|
| Drugs | DAA | Trial | Genotypes | Patients | Sponsor |
|
| Faldaprevir + BI207127 + Ribavirin | PI NS3/4A + NNPI NS5B | Phase 3 | 1 | Treatment-naive | Boehringer Ingelheim |
| Simeprevir + TMC647055 + Ritonavir + Ribavirin | PI NS3/4A + Ritonavir potentiated
NNPI NS5B | Phase 2a | 1 | Treatment-naive and previous relapsers | Janssen R & D |
| Simeprevir + Sofosbuvir + Ribavirin | PI NS3/4A + NPI NS5B | Phase 2a | 1 | Null responders | Janssen R & D |
| Asunaprevir + Daclatasvir | PI NS3 + NS5A inhibitor | Phase 3 | 1b | Treatment-naive | Bristol-Myers Squibb |
| ABT450 + Ritonavir + ABT267 | Ritonavir potentiated PI NS3 + NS5A inhibitor | Phase 2 | 1b, 2 | Treatment-experienced | AbbVie (prior sponsor, Abbott) |
| ABT450 + Ritonavir + ABT267 + ABT333 | Ritonavir potentiated PI NS3 + NS5A inhibitor + NNPI NS5B | Phase 2 | 1 | Treatment-experienced | Abbott |
| Danoprevir + Ritonavir + Mericitabine + Ribavirin | Ritonavir potentiated PI NS3/4A + NPI NS5B | Phase 2 | 1 | Treatment-experienced | Hoffmann-La Roche |
| Sofosbuvir + GS5885 + Ribavirin | NPI NS5B + NS5A inhibitor | Phase 3 | 1 | Treatment-experienced | Gilead Sciences |
| Sofosbuvir + Ribavirin | NPI NS5B | Phase 3 | 2, 3 | Treatment-naive and Treatment-experienced | Gilead Sciences |
| Setrobuvir + Danoprevir + Ritonavir + Mericitabine | NNPI NS5B + Ritonavir potentiated PI NS3/4A + NPI NS5B | Phase 2 | 1 | Treatment-naive and null responders | Hoffmann-La Roche |
| Asunaprevir + Daclatasvir + BMS791325 | PI NS3 + NS5A inhibitor + NNPI NS5B | Phase 2 | 1 | Treatment-naive | Bristol-Myers Squibb |
| Daclatasvir + Sofosbuvir + Ribavirin | NS5A inhibitor + NPI NS5B | Phase 2 | 1, 2, 3 | Treatment-naive | Bristol-Myers Squibb |
| GS5885 + GS9451 + Tegobuvir + Ribavirin | NS5A inhibitor + PI NS3/4A + NNPI NS5B | Phase 2 | 1 | Interferon ineligible or intolerant subjects | Gilead Sciences |
|
